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Homology modelingVoltage-gated Ca2+ channels allow for Ca2+-dependent intracellular signaling by directly mediating Ca2+ ion
inﬂux, by physical coupling to intracellular Ca2+ release channels or functional coupling to other ion channels
such as Ca2+ activated potassium channels. L-type Ca2+ channels that comprise the family of Cav1 channels
are expressed in many electrically excitable tissues and are characterized by their unique sensitivity to
dihydropyridines. In this issue, we summarize genetic defects in L-type Ca2+ channels and analyze their role
in human diseases (Ca2+ channelopathies); e.g. mutations in Cav1.2 α1 cause Timothy and Brugada syndrome,
mutations in Cav1.3 α1 are linked to sinoatrial node dysfunction and deafness while mutations in Cav1.4 α1 are
associated with X-linked retinal disorders such as an incomplete form of congenital stationary night blindness.
Herein, we also put the mutations underlying the channel's dysfunction into the structural context of the
pore-forming α1 subunit. This analysis highlights the importance of combining functional data with structural
analysis to gain a deeper understanding for the disease pathophysiology as well as for physiological channel
function. This article is part of a Special Issue entitled: Calcium channels.
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Voltage-gated calcium channels (VGCCs) govern important physio-
logical functions such as contraction, secretion, neurotransmission, and
gene expression in many different cell types by mediating Ca2+ entry
into electrically excitable cells in response to membrane depolarization
[1]. VGCCs, like other ion channels, do not operate as isolated proteins,
but instead form signaling complexeswith signalingmolecules, receptors,
other types of ion channels [2,3]. A central pore-forming α1-subunit
determines most of the channel's biophysical and pharmacological
properties. In the cell membrane, the calcium channels form a hetero-
oligomeric complex with auxiliary β- and α2δ-subunits, and in somem channels.
x: +43 1 4277 9641.
at (A. Koschak).
-NC-ND license.cases δ-subunits. VGCCs can be divided into the group of L-type calcium
channels (LTCCs, Cav1 family) and non-LTCCs (Cav2 and Cav3 family).
We will focus in this review on LTCCs.
The LTCCs comprise the isoforms Cav1.1, Cav1.2, Cav1.3 and Cav1.4.
Their functional diversity reaches from excitation–contraction coupling
in muscle, to stimulus secretion coupling in sensory and endocrine cells,
cardiac pace-making, as well as neuronal ﬁring to learning and memory
[1]. They can be distinguished pharmacologically from other VGCCs by
their high sensitivity towards organic Ca2+ channel blockers and activa-
tors. Among those, dihydropyridines (DHPs) proved especially important
because of their very high binding afﬁnity, their high selectivity for LTCCs
and their diversity, being both Ca2+ channel blockers (e.g. isradipine, ni-
fedipine) and Ca2+ channel activators (e.g. BayK 8644) [4,5]. The Ca2+
channel blockers in clinical use (as suchnifedipine, amlodipine, verapamil
and diltiazem) have mainly cardiovascular effects as they preferentially
block Cav1.2 channels in the cardiovascular tissue.
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tissues including sinoatrial nodes, heart atria, neurons, chromafﬁn
cells and pancreatic islets. In particular, Cav1.3 serves an important
role in the sinoatrial node [6] and in chromafﬁn cells [7], and they
shape neuronal function [8] and help to support pace-making in vulner-
able dopaminergic substantia nigra neurons [9]. Importantly the use of
DHPs has been shown to be associated with a decreased incidence of
Parkinson's disease in humans [10]. In the hippocampus Cav1.2 medi-
ates long-term potentiation, spatial learning andmemory [11], whereas
Cav1.3 mediates long-term potentiation in the amygdala and partici-
pates in the consolidation of fear memory [12].
Cav1.4 channels are predominantly expressed in retinal cells
where they play an important role, as evident from mutations in
the voltage-gated calcium channel gene CACNA1F encoding Cav1.4
LTCCs that cause several forms of retinal diseases in humans
(OMIM: 300071, 300476, 300600). Cav1.4 knock-out mice support
this view as these mice show severe visual deﬁciencies [13,14].
Cav1.4 expression is also reported in dorsal root ganglia neurons
[15], mast cells [16] and T-lymphocytes [17].
Cav1.1 channels possess a more restricted expression pattern. This
channel is expressed almost exclusively in skeletal muscle cells. Confor-
mational changes of voltage-sensing domains in Cav1.1 are transmitted
by a mechanical linkage to the associated ryanodine receptors that re-
lease Ca2+ from the sarcoplasmic reticulum [1].
All VGCCs are capable of sensing intracellular Ca2+ levels. This is very
likely a safety mechanism to protect cells from calcium overload via
activity-dependent feedback mechanisms such as Ca2+-dependent inac-
tivation (CDI), mediated by C-terminally bound calmodulin [18,19].
Mechanisms that inhibit CDI play an important role in sensory cells (as
such for Cav1.4 in retinal cells and for Cav1.3 in auditory cells, see [20])
allowing the inducement of graded and tonic presynaptic depolarization
and making neurotransmitter release dependent on sustained activation
of presynaptic LTCCs.
Diseases caused by mutations in genes encoding ion channel sub-
units or their regulatory proteins are referred to as ‘channelopathies’.
A large number of distinct channel dysfunctions have been described
to be caused by mutations in the channel's 1α subunits. Mutations in
LTCCs may result in a loss-of-function, in which the LTCC mediated
Ca2+ inﬂux is (much) reduced or completely abolished whereas
gain-of-function mutations confer new or enhanced activity. How-
ever, apparently such enhanced activity has an unwarranted positive
connotation. Gain-of-function mutations may result in enhanced
Ca2+ inﬂux, but this increased sensitivity does not necessarily result
in improved signaling. Instead, this might result in a loss-of-control
of existing Ca2+ signaling pathways.
Here we summarize the role of selected LTCCs in human diseases
that are caused by genetic defects in these Ca2+ channels (‘Ca2+
channelopathies’) andwe discuss the functional effects of the structural
aberrations within the pore-forming α1 subunit that underlie the
channel's dysfunction. Table 1 summarizes Cav1.2, Cav1.3 and Cav1.3
α1 subunit related diseases. Mutations in the Cav1.1 channel, leading
to hypokalemic periodic paralysis and malignant hyperthermia sensi-
tivity are reviewed elsewhere [21].We elaborate on common structural
‘hotspots’ that result in either loss- or gain-of-channel function in all the
three LTCCs and discuss them in the structural context of a Cav1.4 chan-
nel homologymodel (Fig. 1 and Table 1). Themodel of the Cav1.4 chan-
nel was created using the structure of NavAB (PDB ID: 3RVY, [22]) as a
template. The sequences of human Cav1.x and NavABwere ﬁrst aligned
with MUSCLE [23], then models of the Cav1.4 channel were created
using MODELLER version 9.8 [24]. The best model based on the DOPE
score was selected for analysis [25].
2. Cav1.2-related channelopathies
Cav1.2 is the predominantly expressed LTCC in the cardiovascular
system. Its dysfunction can cause severe cardiac diseases in humansoften associated with sudden cardiac death. Patients carrying muta-
tions in the CACNA1C gene – that encodes for the Cav1.2 channel –
may suffer from Timothy syndrome (TS, [26,27]), Brugada syndrome
(BS, [28]), and in some cases are diagnosed together with shorter as
normal QT intervals (sQT; [29]) and early repolarization syndrome
(ERS, [29]). Among those, TS is a multiorgan disease; the patients
may suffer from syndactyly (fusion of ﬁngers and/or toes), immune
deﬁciency, intermittent hypoglycemia, cognitive abnormalities and
autism [26,27] in addition to cardiac arrhythmias that are often asso-
ciated with sudden death. Cav1.2 mutations from patients with BS so
far functionally analyzed led to a loss-of-function (Tables 1 and 2)
showing a still controversially discussed [28–30] loss-of-trafﬁcking
phenotype. In contrary, two mutations in patients suffering from TS
show a Cav1.2 channel gain-of-function [26,27]. The ventricular ar-
rhythmias caused by these mutations are severe and the majority
of TS patients seldom survived beyond the age of three years. The
two mutations were initially identiﬁed as de novo mutations. How-
ever, they may actually also represent parental mosaicism [27,31].
The low number of reports in the literature of patients/families car-
rying Cav1.2 (and also Cav1.3) mutations (Table 1) might be due to
mild(er) phenotypes that could eventually escape detection in case
of somatic mosaicism.
The gain-of-function of a glycine-to-serine mutation at position 402
(Gly402Ser) at the cytoplasmic end of segment IS6 (Fig. 1) resulted in a
strong reduction of voltage-dependent inactivation (VDI, [26]). A simi-
lar effect that included a slight shift in the voltage-dependence of acti-
vation was observed for a glycine-to-arginine substitution just four
amino acids downstream at position 406 (Gly406Arg) in helix 6. The
change of channel function was irrespective of the co-expressed
β-subunit [27,32]. Importantly the same mutation at position 406 can
be located in exon 8A [VNDAV-coding exon] where it results in a rela-
tively mild phenotype of Timothy syndrome (named TS1 in [26]) com-
pared to its occurrence in the alternative exon 8 (MQDAM-coding
exon). The latter more severe variant named TS2 [27] can be rational-
ized by the higher expression of exon 8 in the heart and brain (80% ver-
sus 20% exon 8A [27]). Neither heterozygous nor homozygous TS2-like
mice were viable. Most likely the predominant expression of exon 8 in
the brain and heart resulted in a lethally high level of mutated channels
[33]. However, heterozygousmice that still carried the inverted neomy-
cin cassette in exon 8A (TS2-neo) survived through adulthood. It is
unclear, whether or not heterozygous TS2-neo mice better tolerated
the mutation because the neo-cassette lowered expression levels of
the mutated channel; supporting biochemical data are missing. Inter-
estingly behavioral phenotyping showed that TS2-neo mice have
normal general health and activity but show a markedly restricted,
repetitive and preservative behavior, altered social behavior, altered
ultrasonical vocalization as well as enhanced tone-cued and contextual
memory following fear conditioning despite displaying normal anxiety
levels [33]. These data suggest that thesemice also show autism-related
behavior corresponding to core aspects of autism and autism spectrum
disorders seen in humans.
Kinetic models suggested that the functional consequences of an al-
most complete loss of VDI of Cav1.2 channels in cardiac cells results in a
prolongation of action potential duration and in increased calcium tran-
sients [34]. This correlates well with the observed prolongation in the
QT interval in the affected individuals. Indeed such effects are evident
from Ca2+ signaling experiments in Timothy syndrome cardiomyocytes
derived from human skin cells of Timothy syndrome patients that were
reprogrammed and induced to produce pluripotent stem cells. Mutation
Gly406Arg led to signiﬁcantly larger and prolonged Ca2+ elevations
suggesting that channel inactivation is important for maintaining timing
and amplitude of the ventricular Ca2+ release [35]. Similar effects were
also observed in iPSC-derived neuronal cells on action potential widening
[36]. Thus, drugs that directly interferewith the Cav1.2 inactivation gating
mechanism are likely to improve cardiac arrhythmias as well as other
severe symptoms affecting TS patients. Yarotskyy and colleagues [37]
Table 1
Diseases associated with mutations in Cav1.2, Cav1.3 and Cav1.4 LTCCs.
LTCC Disease/syndrome
(abbreviation)
Mutation(s) Number of affected families/individuals
(as far as described clearly in the references)
Cav1.2 Timothy syndrome (TS) p.Gly402Ser, p.Gly406Arg (exons 8 and 8A) 17 patients (4 case studies), refs. 3, 4
Brugada syndrome (BS) p.Ala39Val, p.Gly490Arg, p.Glu850del, p.Glu1115Lys,
p.Glu1829_Gln, 1833dupl, p.Val2041Ile, p.Cys1837Tyr,
p.Arg1880Gln, p.Asp2130Asn
2 patients, ref. 1
BS & short QT (SQT) 9 patients, ref. 2
Early repolarization syndrome (ERS) 1 patient, ref. 2
Cav1.3 Sinoatrial node dysfunction and
deafness (SANDD)
p.403_404insGly 2 Pakistani families/6 affected males, 1 affected
female, ref. 6
Cav1.4 Congenital stationary night blindness
type 2 (CSNB2)
Exonic mutations (see Table 2)
Intronic splice site mutations: IVS4-2A>G,
2387-1(G>C), 2673+3(G>A), 2674-2,3(delCA),
2571+1G>C, IVS24+1G>A, IVS28-1 GCGTC>TGG,
3942+2(T>A), 3942+2(T>A), 4101-1(G>C), IVS40-2A>G
Missense: 33 families, refs. 7–11, 14, 16, 17, 23, 24
Truncations: 24 families, refs. 7–11, 17, 24
Deletions/insertions: 35 families, refs. 7–12, 21, 23
Splice site mutations: 11 families, refs. 9–11
X-linked retinal disorder (XRD) similar to
CSNB2 but more severe phenotype
p.Ile745Thr 1 New Zealand (Maori) family, ref. 16
Cone–rod dystrophy (CORDX3) Splice site mutation: IVS28-1
GCGTC>TGG
1 Finnish family/7 affected males, 10 female
carriers, 33 non-affected family members, ref. 19
Åland Island eye disease (AIED) p.del1211–1247 1 Finnish family/6 samples from affected males, ref. 21
Night-blindness-associated transient tonic
downgaze (NATTD)
p.Trp349stop, p.Gly359Arg, p.Pro1489Arg 8 boys, among those 2 pairs of maternally related
half-brothers, 2 cousins, and 2 siblings, ref. 24
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that roscovitine [originally developed as a selective blocker of cyclin-
dependent kinases [38] that was undergoing phase II clinical trials as
an anticancer drug] enhances VDI [39,40]. Therefore, roscovitine could
have a potential to restore the electrical and calcium signaling properties
of cardiomyocytes from Timothy syndrome patients [35].
Other pro-arrhythmic factors beyond the loss of VDI in TS have been
attributed to aberrant Cav1.2 phosphorylation. Spontaneous mode 2 gat-
ing that appeared to depend on CaMKII-dependent protein phosphoryla-
tion was observed in a rabbit Cav1.2-Gly436Arg mutation (homologue to
the human mutation Gly406Arg) that involved the downstream serine
residue 439 [41]. Rat ventricular myocytes (lenti-)virally transduced
with the mutant Cav1.2-Gly406Arg channel exhibited increased CaMKII
sensitivity. CaMKII inhibitors reversed action potential prolongation in
TSmyocytes [42]. Transgenicmice that also expressed the rabbit homolog
mutation (named in Cav1.2-LQT8 in reference [43]) expectedly showed
slow calcium current inactivation in both ventricular myocytes and
mouse embryonic ﬁbroblasts. Normal calcium current inactivation was
restored in myocytes from mice that were crossed with mice lackingFig. 1. Location of human mutations in Ca2+ channel Cav1.2, Cav1.3 and Cav1.4 α1 subunit
Cav1.2; 1.3, Cav1.3; 1.4, Cav1.4). For Cav1.4, only missense and truncation mutants were inc
served functional changes. n.i.; not yet investigated. Loss-of-function reported due to: e exp
motif; IQ, IQ-motif; CTM, C-terminal modulator [73]. Potential structure–functional hotspothe A-Kinase anchoring protein AKAP150 [43]. In addition channel ex-
pression and spatial distribution in the ventricular myocyte was changed
and the channels seemed to form multiple clusters in the sacrolemma.
The authors suggested amechanism that requires AKAP150during defec-
tive inactivation and for coupled gating events in Cav1.2 TS mutant
myocytes previously described by Navedo and colleagues [44]. Such
mechanism implies coupling of Cav1.2 channels by transient interactions
between neighboring channels via their intracellular C-termini. The
mechanism per se however is still controversially discussed in the ﬁeld
[44–48].
The two amino acid residues Gly402 and Gly406 identiﬁed a region
forming a critical “hotspot” for channel gating (Figs. 1 and 3). Interest-
ingly, the Gly402 corresponds to Gly369 in Cav1.4 α1 subunits. This
residue is mutated to arginine in patients with the incomplete form of
congenital stationary night blindness (CSNB2) andwas found to strong-
ly inhibit VDI [49–51]. Moreover, the insertion of an additional glycine
residue at position 403 in Cav1.3 α1 subunits causes a loss-of-function
mutation in patients that are affected with sinoatrial node dysfunction
and deafness (SANDD) [52].s. The numbers refer to the position of the mutations in the corresponding LTCC (1.2,
luded, insertion and deletion mutants were omitted for clarity. Colors indicate the ob-
ression deﬁciency, f functional defect, p predicted. Abbreviations: ‘EF’, putative EF-hand
ts are highlighted by yellow boxes.
Fig. 2. Cav1.4 channel mutation summary. The position of all listed mutants is shown in an overview of the transmembrane domain of the Cav1.4 channel, seen from the extracellular
site. The channel sequence is color coded from N- to C-terminus from red to blue. Residues that show a loss-of-function mutation are indicated in red; residues, in which the
mutation is accompanied by a gain-of-function, are depicted in green; mutation of residues shown in orange does not change channel function; residues, of which the effect of
mutation has not yet been experimentally described, are shown in gray.
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as their side chain consists of only a hydrogen atom; they i) allow
close association of helices as e.g. observed in the GXXXG helix–helix
crossing motif, and ii) introduce ﬂexibility in helices by providing a
bending point. A GXXXG sequence is present in the IS6 helix of Cav1.x
channels. The respective residues corresponding to Gly369 in the
IIS6–IVS6 helices of Cav1.4 channels are A755, G1134 and A1438.
These residues interface with the S4–S5 linker helix, suggesting that a
small residue like glycine or alanine (the second smallest residue) is re-
quired. The side chain at this position interacts with the end of the S4–
S5 linker helix in both states of the gate: in the closed gate as found in
NavAB [22] and in the open gate as observed in Kv1.2–2.1 [53]. It is
conceivable that tight coupling of the S4–S5 linker to residue Gly369
is required for correct gate opening. A change in function by mutation
at position Gly402 (in Cav1.2) or Gly369 (in Cav1.4) showing altered
channel opening by interfering with this interaction would therefore
also be expected from the model.
3. Cav1.3-related channelopathy
Until now only one human disease syndrome resulting from a muta-
tion in the CACNA1D gene – encoding the Cav1.3 α1 subunit – was
reported. The reason for this low incidence could be that mutations
cause embryonically lethal dysfunction in the homozygous state or that
the phenotypes are so mild that they pass unnoticed in the heterozygous
state as observed in Cav1.3 knock-out mice [6]. Members of two consan-
guineous families carried an insertion mutation that introduced anadditional glycine residue at position 403 (403_404insGly) in the highly
conserved, alternatively spliced region in domain I. This insertion occurs
in the S6 helix, next to the channel pore (Fig. 1, position indicated by
Gly369 of the Cav1.4 channel in Figs. 3A, C and 4B). The resulting mutant
channel is non-conducting and shows abnormal voltage-dependent gat-
ing [52]. The patients presented with a congenital cardiac (sinoatrial
node arrhythmia at rest) and auditory (severe to profounddeafness) phe-
notype. These data manifested a similar role of Cav1.3 in humans and
mice, becausemousemodels predicted no clinical symptoms in heterozy-
gous patients, but showed congenital hearing impairment and sinoatrial
node dysfunction in homozygous individuals [6]. Cav1.3 channels have
also been reported to mediate Ca2+ oscillations underlying autonomous
pace-making in dopaminergic substantia nigra neurons in mice. Such
mechanism renders these neurons more susceptible to neurotoxicity
[9,54] and therefore suggests a delicate role of Cav1.3 channels in the
pathophysiology of Parkinson's disease. No symptoms have been yet ob-
served in patients that would indicate a central neuronal disease (which
might also be because neuronal consequences have not yet become ap-
parent due to the youth of the patients; age 15–24). Cav1.3 channels
seem prominently expressed in the mouse retina [12]. They regulate the
light peak of the electroretinogram (ERG) [55] and might contribute at
least partly to the b-wave component in the ERG [12]. Ophthalmological
investigation of patients, however, did not indicate any visual defect to
light. Structural differences betweenmouse and human retinas could ex-
plain the diverging observations. The human mutation 403_404insGly
was only found in exon 8B, not in the more widely expressed exon 8A
[52]. If exon 8A would be the predominant splice variant in the retina,
Table 2
Disease causing mutations in human Cav1.2, Cav1.3 and Cav1.4 alpha1-subunits. Different types of mutations have been reported: M, missense; T, truncation; D, deletion; I, inser-
tion; Dupl, duplication; bp, base pair. Splice site mutations are not included in the table. References: 1: Antzelevitch et al., 2007; 2: Burashnikov et al., 2010; 3: Splawski et al., 2004;
4: Splawski et al., 2005, 5: Etheridge et al., 2011; 6: Baig et al., 2011; 7: Strom et al., 1998; 8: Bech-Hansen et al., 1998; 9: Boycott et al., 2001; 10: Nakamura et al., 2001; 11: Wutz et
al., 2002; 12: Jacobi et al., 2003; 13: McRory et al., 2004; 14: Hemara-Wahanui et al., 2005; 15: Hoda et al., 2005; 16: Hope et al., 2005; 17: Zeitz et al., 2005; 18: Hoda et al., 2006; 19:
Jalkanen et al., 2006; 20: Singh et al., 2006; 21: Jalkanen et al., 2007; 22: Peloquin et al., 2007; 23: Zeitz et al., 2009; 24: Simonsz et al., 2009. Numbering of mutations refers to the
following Genbank accession numbers: Cav1.2: NM_000719, UNIPROT entry number: Q13936, Cav1.3: EU363339, UNIPROT entry number: B0FYA3, Cav1.4: UNIPROT entry number:
O60840-1, isoform 1. Numbering referring to Genbank accession number JF701915 in publications showing functional data is added in parenthesis (this isoform contains exon 9a
and therefore lacks 11 amino acids). * indicates that loss of channel function is highly predicted.
Cav1.4
Exon Type Loss-of-function Ref Exon Type Gain-of-function Ref Exon Type CTM-function
impaired
Ref Exon Type Unknown
function
Ref
2 T p.Arg50stop* 9 8 M p.Gly369Asp 7, 9, 11,
13, 16
41 T p.Lys1602stop
(1591)
7, 11,
20
2 M p.Cys74Arg 11,
24
2 D/I c.151del5* 11 17 M p.Phe753Cys
(742)
11, 23 46 T p.Arg1827stop
(1816) predicted20
11 6 M p.Gly261Arg 11
2 T p.Arg82stop* 9, 11 17 M p.Ile756Thr
(745)
14, 16 7 D/I c.951del3bp 9
4 D/I c.271del4 bp/ins34 bp,
del/ins net 30 bp*
9, 10 8 M p.Gly359Arg 24
6 M p.Ser229Pro 11, 15 16 M p.Asn746Thr 23
7 D/I c.904insG* (709) 10 21 M p.Leu860Pro
[849]
11
7 D/I c.935delA* 23 23 M p.Asp944Tyr 23
8 T Trp360stop 24 28 M p.Glu1145Lys 23
9 D/I c.1218delC* 8, 9 29 M p.Arg1182Pro 11
10 T p.Gln428stop* 11 31 M p.Ser1265Ile 17
13 M p.Arg519Gln (508) 7, 9,
18, 23
33 M p.Arg1296Ser 17
14 T p.Arg625stop* 9, 11 38 M p.Leu1486Pro 23
15 T p.Arg691stop* 17 38 M p.Pro1492Ala 23
21 T p.Arg895stop* 8, 9,
17
38 M p.Cys1499Arg 11
24 T p.Arg969stop* 7, 11 38 M p.Pro1500Arg 11,
24
24 T p.Arg978stop* 10 39 M p.Leu1508Pro 11
25 M p.Gly1018Arg (1007) 11, 23 47 D/I c.5665delC 9
27 D/I c.3158delG* 9
27 D/I c.3166-3167insC*
(c.3133-3134insC)
7, 8, 9,
11
27 M p.Arg1060Trp (1049) 7, 11,
22
27 M p.Leu1079Pro (1068) 11, 15
29 D/I c.3504del2bp 23
30 D/I p.del1222-1258 21
27 M p.Leu1079Pro (1068) 11, 15
29 D/I c.3504del2bp 23
30 D/I p.del1222-1258 21
27 M p.Leu1079Pro (1068) 11, 15
29 D/I c.3504del2bp 23
30 D/I p.del1222-1258 21
Cav1.2
Exon Type Loss-of-function Ref Exon Type Gain-of-function Ref Exon Type Unknown function Ref
2 M p.Ala39Val 1 8 M p.Gly402Ser 4 19 D/I p.Glu850del 2
10 M p.Gly490Arg 1 8 M p.Gly406Arg 4 26 M p.Glu1115Lys 2
43 Dupl p.Glu1829_Gln 1833dupl 2 8A M p.Gly406Arg 3, 5 42/43 M p.Cys1837Tyr 2
46 M p.Val2041Ile 2
Cav1.3
Exon Type Loss-of-function Ref
8B D/I p.403_404insGly (c.1208_1209insGGG) 6
1602 T. Stockner, A. Koschak / Biochimica et Biophysica Acta 1828 (2013) 1598–1607then this could also well explain the absence of visual disturbances in the
patients.
The reported Cav1.3 glycine insertion affects a functionally sensi-
tive region at the cytoplasmic end of the inner pore-lining S6 helix in
domain I. Insertions of residues in α-helices can have two outcomes:
the creation of a π-helical element with 5 instead of 4 residues per
helical turn that is larger and at the same timemore ﬂexible, or a reg-
ister shift that results in a 100° rotation of all downstream residues.
In either case we expect a dramatic change in function. The larger
size of the π-helical element would directly shrink the pore in the
gating region. The increase in ﬂexibility could have an additional
and potentially more dramatic effect, as it might disengage the S6helix motion of gate opening that is triggered by the voltage-sensor
bending of the otherwise rigid S6 helix. This could result in a closed
gate, driven by hydrophobic interactions to the other S6 segment
within the gate region, despite a gate opening conformational
change in the voltage sensor. If instead the insertion of the glycine
induces a register shift, then the helix S6 would present to its inter-
action partner downstream of the insertion the residue adjacent to
the one found in the wildtype channel. Therefore every interaction
with the S6 helices in the other 3 domains would change and
would affect the interaction with the S4–S5 linker helix. Thus, this
mutation could directly compromise the structural communication
with the voltage-sensor and prevent pore opening.
Fig. 3. Hotspot ofmutations in Cav1.x channels. Panel A shows the structure of Cav1.4with a focus on the interface between the IS4–S5 linker and IS6 at the intracellular side. Residues at position
Gly369 (corresponding to position 402 in Cav1.2 and 403 in Cav1.3) andGly373 (which corresponds to positionGly406 in Cav1.2) at the end of S6 are highlighted. A glycine residue (indicated as
Gly255 in Cav1.4) at the end of S5 is highly conserved among transmembrane domains (D1–D4) in all Cav1.x channels. Panel B shows the alignment of the S4–S5 linker and the S5 transmem-
brane helices in D1–D4 of human Cav1.x sequences. Panel C shows the alignment of the S6 helices of the Cav1.x channels. Arrows indicate the position of hotspot residues. Residue color coding
follows the convention of Clustal (http://www.jalview.org/help/html/colourSchemes/clustal.html). Sequence numbers are given as observed in the ﬁrst TM domain of Cav1.4.
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Several X-linked visual disorders that share a variety of clinical
symptoms have been associated with mutations in the CACNA1F gene
— that encodes for the Cav1.4 α1 subunit. As such Åland Island eye dis-
ease (AIED, [56]), cone–rod dystrophy (CORDX3, [57]), X-linked retinal
disorder (XRD, [58]), night blindness-associated transient tonic
downgaze (NATTD, [59]) and incomplete congenital stationary night
blindness (iCSNB, CSNB2, [49,50,60–62]) have been reported. The ma-
jority of mutations were identiﬁed among patients originally diagnosed
with CSNB 2.
CSNB2 is characterized by variable and often mild clinical symp-
toms. The term is however misleading because night blindness is
not necessarily the major complaint. Typical symptoms in CSNB2 are
moderately low visual acuity, myopia, nystagmus and variable levels
of night blindness but one or more of these symptoms may be absent
[60]. CSNB2 is therefore diagnosed on the basis of ERG abnormalities.
CSNB2 patients show an abnormal dim scotopic ERG and a typical neg-
ative bright-ﬂash ERG which has large a-waves, but severely reducedFig. 4. Loss-of-function mutations. The position of loss-of-function mutations are highlight
exterior, while panel B shows the channel from the cytosolic site with a focus on the cen
position of the insertion mutation in Cav1.3 at position 403_404 is highlighted in magentab-waves. Oscillatory potentials are also missing [63]. This ERG pheno-
type is compatible with a defect in neurotransmission within the retina
between photoreceptors and second-order neurons, very similar to the
phenotype described in Cav1.4 knock-out mice [13]. Upon light absorp-
tion in the photoreceptor outer segments the closure of cGMP-gated
cation channels hyperpolarizes the cells to below −55 mV [64]. In
the dark, photoreceptors depolarize to a resting membrane potential
of −36 to −40 mV, thereby enhancing tonic neurotransmitter (gluta-
mate) release downstream [65]. Release occurs at specialized ribbon-
type synapses where LTCCs are the predominant channels controlling
neurotransmitter secretion at the ribbon synapses of retinal photorecep-
tors [66,67] and of cochlear inner hair cells [6,68,69]. Only a few channels
that activate rapidly at relatively negative voltages (b−40 mV,
[66,70,71]) and inactivate slowly are needed to support tonic release
[66]. In cultured mammalian cells, heterologously expressed Cav1.4
currents indeed activate rapidly, open at negative membrane potentials
and thereby allow the channel to conduct Ca2+ at potentials negative
to−40 mV. In addition, the Cav1.4 currents show slowVDI accompanied
by complete absence of calcium-dependent inactivation (CDI) duringed on the Cav1.4 channel model. Panel A displays a view on the channel from the cell
tral S6 helices. Loss-of-function mutations described for Cav1.4 are shown in red. The
by the corresponding residue G369 in Cav1.4.
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inactivation kineticswere accelerated at near physiological temperatures
but the window current was still preserved [74]. Dysfunction of Cav1.4
channels at release sites ofmammalian photoreceptors in the outer plex-
iform layer is expected to decrease also photoreceptor neurotransmitter
release capacity and impair signaling to second-order retinal neurons
[75]. Cav1.4may also contribute to the LTCC currentsmeasured in bipolar
cell terminals as indicated by the Cav1.4 immunostaining inmouse inner
plexiform [12,13,76–78].
So far more than 50 structural aberrations were identiﬁed in the
Cav1.4α1 subunit gene of CSNB2 patients (Table 2). CSNB2mainly affects
males, because of the X-linked condition of Cav1.4 channel dysfunction.
However, if the CACNA1F gene is subject to X-inactivation, then heterozy-
gote females can be affected as well [79] by showing cellular mosaicism
for healthy/mutant Cav1.4 channels. As outlined in Table 2 and Fig. 2,
we can classify three groups of Cav1.4mutations on the basis of their func-
tional effects: i) loss-of-functionmutations, ii) gain-of-functionmutations
and iii) mutations causing impaired C-terminal modulator (CTM) func-
tion (described below). It is not completely understood how the different
functional channel phenotypes can all result in defective retinal synaptic
transmission underlying CSNB2 symptoms. A majority of mutations are
predicted to cause severe structural changes so that they are unlikely to
from functional channels, often due to premature truncation (Table 2,
marked with *). Nonsense-mediated mRNA decay eliminates mRNA
containing pre-mature stop codons in regions followed by splice sites at
a distance of 50–55 nucleotides downstream [80]. Therefore, the truncat-
ed Cav1.4 channels might not even be expressed. Other point mutations
abolish channel activity. Among those, no channel activity was observed
for mutations Ser229Pro, Gly1018Arg, Arg1060Trp and Leu1079Pro mu-
tations expressed in Xenopus laevis oocytes (Ser229Pro, Leu1079Pro,
[51]) or tsA-201 cells (Gly1018Arg, Arg1060Trp [81]) although their α1
subunits were expressed at levels indistinguishable from wildtype chan-
nels. Only in the Leu1079Pro mutant channel current could be elicited
in the presence of the calcium channel activator BayK8644 (BayK), show-
ing slightly faster inactivation kinetics compared towildtype+BayK [51].
Ser229 is located in the middle of the IS4–S5 linker (Fig. 3B). Mutation
Ser229Pro in the center of the IS4–S5 linker helix exchanges the
polar amino acid serine with the helix breaking, but hydrophobic
amino acid proline. Proline has helix destabilization properties, as
it misses the amide proton essential for the helix stabilizing back-
bone hydrogen bond to the carbonyl oxygen of the amino acid in
the preceding helical turn. In addition, the serine to proline mutation
increases the hydrophobicity at position 229, which is oriented to-
wards the gate and interacts with the IIS6 helix (Fig. 4B). This change
in property could therefore have a stabilizing effect, counteracting
the helix destabilization and therefore explaining why expression
was not signiﬁcantly affected. Signaling of the voltage sensor de-
pends on a mechanical communication transmitted by the S4S–S5
linker helix. Ser229Pro adds a kink or alternatively shortens the
S4–S5 helix by one helical turn, thereby most likely interrupting
the mechanical communication in both cases.
Residues Gly1018 and Leu1079 come into close proximity in the
tertiary structure (see Fig. 4A) of the Cav1.4 ion channel. Gly1018 is
found at the extracellular end of IIIS5, interfacing with IIIS6. The
mutation Gly1018Arg introduces the positively charged arginine
instead of the small glycine. Water exposed arginines have been
previously described to support folding of transmembrane proteins
[82–84]. The Leu1079Pro mutation exchanges one hydrophobic
amino acid by another, but destabilizes the beginning of the domain
III pore helix. Bothmutations, the stark increase in the side chain size
of the Gly1018Arg mutation and the helix binding properties of
the Leu1079Pro mutation, could potentially change the geometry
of the selectivity ﬁlter and block ionic ﬂux.
Reduced protein expression was seen in mutants Arg519Gln and
Leu1375His in transfected tsA-201 cells; this effect appeared to be
temperature-dependent [85]. The authors found no changes in gatingproperties for Arg519Gln and minor changes affecting inactivation
properties and channel recovery (Leu1375His) when the mutated
channels were heterologously expressed in X. laevis oocytes. The ex-
pression deﬁcit observed for mutant Arg519Gln might be explained
by its critical position at the end of the amphipathic I–II linker, interfac-
ing with the end of the IIS2 helix (Fig. 2). An arginine in this position
could play a dual role, namely interact with the negatively charged
phosphate group of phospholipids and at the same time stabilize the
negative dipole of the C-terminus of helix IIS2. A glutamine in the
Arg519Gln mutation cannot fulﬁll the same role.
Similarly to the pore mutation Leu1079Pro, the mutation Leu1375His
is located in domain IV in almost the same position of the pore helix (rel-
ative shift by one residue). In both cases a leucine in the core of the
domain is affected.While themutation Leu1079Promaintains the hydro-
phobic property of residue 1079,mutation Leu1375His introduces a bulky
polar side chain. The reduced expression could potentially be attributed to
this change. Nevertheless the Leu1375His mutation should maintain the
structural integrity of the pore helix that possibly explains the only
minor functional changes.
The truncation mutant Trp1451stop, which could theoretically form
a functional channel because it contains all transmembrane segments
and a portion of the C-terminal tail, did not express at the protein
level in one study [51] butwas indicated to normally express in another
study (mutation W1459stop in [16]).
Remarkably,McRory and colleagues found that the twomissensemu-
tations Gly674Asp and Ala928Asp exerted no detectable changes in the
activation, inactivation, or conductance properties of expressed Cav1.4
channels [16]. ResidueAla928 can be found outside themembranewithin
the intracellular IIIS2–S3 loop (Fig. 2). An alanine-to-aspartic acid muta-
tion can probably be accommodated in this water exposed loop. Themu-
tation of Gly674Asp (Fig. 4A) is located at the end of helix IIS5. This
glycine is conserved in all four S4 helices of the human Cav1.x channels
(see Fig. 3B; the corresponding residue G255 in ﬁrst transmembrane do-
main of Cav1.4 is indicated). It is intriguing, that the corresponding
Gly1018Arg mutation strongly affects function (see above), while the
Gly674Asp mutation is functionally silent (Fig. 4A).
The gain-of-function mutations reported so far promote enhanced
Ca2+ entry through the channel by vastly slowed VDI accompanied by
a pronounced depolarizing shift in the voltage-dependence activation
[16,51,79,81]. The gain-of-function mutations Gly369Arg, Phe753Cys
and Ile756Thrmight therefore signiﬁcantly increase Ca2+ inﬂux during
illumination at negative voltages (at around−55 mV physiologically).
At the same time this effectwould reduce the increase upon depolariza-
tion (at around−35 mV physiologically) leading to a reduced dynamic
range in the photoreceptor. Accordingly, also the glutamate release
might be changed and could explain why synaptic transmission is re-
duced in CSNB2 retinas. Alternatively the expected increased calcium
inﬂux might trigger retinal cell death and thereby cause an overall
loss-of-function. Neither hypothesis is yet corroborated. The hyperpo-
larizing shift in Cav1.4 channel activation (around 30 mV) was most
pronounced in mutation Ile756Thr, which was identiﬁed in a New
Zealand family. The affected familymembers showed an unusual sever-
ity of the phenotype and an association with intellectual disability in
males, and also heterozygote female family members had clinical and
ERG abnormalities [58,79]. A pronounced negative shift in channel acti-
vation was also reported for themutation Gly369Arg [51]. The group of
McRory found only a slight, though statistically signiﬁcant increase in
the slope factor of the activation curve and a less pronounced shift of
the half-activation potential with Ca2+ as compared to Ba2+ used as
charge carrier for the mutation Gly369Arg ([16]; possible reasons for
this ﬁnding have been discussed in detail in reference [51]). A pro-
nounced channel gating activity is however well supported from the
structural model that we provide. As depicted in Fig. 5, residue Gly369
is clearly located at the channel gate. As suggested above, a small resi-
due is proposed to be required in position 369 to allow efﬁcient gate
closing, while larger residues would collide with the amphiphilic S4–
Fig. 5. Gain-of-function mutations. The gain-of-function mutations are highlighted in green on the Cav1.4 channel model. Panel A shows a side view of the transmembrane domain
of the channel, while in panel B the cytosolic side of the channel is exposed. The three gain of function mutations of Cav1.4 are shown in dark green, while residue G373, correspond-
ing to G402 in Cav1.2, is shown in light green.
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score 4.80) pore oriented residue (Figs. 2 and 5), while cysteine shows
a hydrophobicity score of 0.49 [86]. A reduction of hydrophobicity and
residue size in the center of the hydrophobic constriction zone of the
gate by the mutation Phe753Cys will most likely increase the open
probability of the mutant channel. Residue Ile756 interfaces with the
adjacent IIIS6 helix andwith the IIIS4–S5 linker helix. Also the Ile756Thr
mutation changes hydrophobicity (Ile=3.48 vs. Thr=0.65) and resi-
due size and might therefore increase the open probability of the chan-
nel by destabilizing the closed conformation, as the polar threonine
residue cannot form the same stable interactions with the adjacent S6
and the S4–S5 linker as Ile756 can.
Truncation mutations in the Cav1.4 C-terminus downstream of
the CDI machinery— either natural, by alternative splicing [87] or in-
troduced by an artiﬁcial mutation [73,88] are of particular interest
because i) they develop an apparent gain-of-function due to a hyper-
polarizing shift of the Cav1.4 mediated window current, ii) they
might reduce Ca2+ inﬂux due to occurrence of CDI [73,88] and iii)
in analogy to recently published data on short Cav1.3 channels [89],
enhanced open probability is expected in truncated Cav1.4 channels.
Which of these processes dominates the phenotype of Cav1.4 mu-
tants with impaired CTM function is still unclear as available exper-
imental data remain inconclusive and because in vivo models do
not yet exist. The analysis of the truncation mutation Lys1602stop
(named K1591X in references [21,73,88]) uncovered that the CDI in
Cav1.4 channels is an intrinsic channel property that depends on
the active suppression by a C-terminal inhibitory domain. Notably
Singh and colleagues found that deletion of the C-terminal domain
not only restored robust CDI but also induced a strong hyperpolarizing
shift of the voltage-dependence of Cav1.4 activation. Accordingly, this
domain was termed “C-terminal modulator” to emphasize this dual
regulatory effect. Similar to Cav1.2 [90] (and as observed also for
Cav1.3 [89]) channels, this intrinsic C-terminal modulation in Cav1.4
channels seems to rely on a binding interaction between a pair of posi-
tively charged residues in a putative α-helical region immediately
downstream of the IQ-motif and a set of three negatively charged resi-
dues in the distal end of the C-terminus (Fig. 1) in the CTM domain.
The critical residues comprising the CTM (and ICDI, as named by
Wahl-Schott and colleagues [88]) were restricted to a highly conserved
stretch of about 25 amino acid residues within the distal C-terminus.
The discovery of the gating modulator in the C-terminus of Cav1.4
channels (Cav1.4-CTM) raises an interesting question on whether this
mode of controlling channel function could be developed into a therapeu-
tic concept for the treatment of patients suffering from channelopathies.
Although partial blockade of mutated Cav1.4 channels seems to be apossibility tomodulate these channels, such an approach is not practica-
ble in vivo because antagonist drugs such as the DHP isradipine [72] are
10- to 20-fold more potent in blocking Cav1.2 compared to Cav1.4 chan-
nels. Therefore the higher concentration required for blocking Cav1.4
channels is expected to cause major Cav1.2-mediated unwanted side ef-
fects. As obvious from the above section, a ‘pharmacological knock-out’
of these channels is largely disadvantageous due to the expected cardiac
side effect. Instead ofmodulating channel functionwith drugs that inter-
act directly with the channel pore and thereby inhibit ion permeation,
molecules that exert their modulatory effects by changing regulatory
channel interactions could serve as study tools, but may even be of ther-
apeutic value. One could speculate thatmimicking the Cav1.4–CTM inter-
actionwould shift the voltage- and calcium-dependence of Cav1.4 gating
back to WT levels in truncated channels and vice versa induction of CDI
via interference with the Cav1.4–CTM interaction could have beneﬁcial
effects in gain-of-function mutations at least within a limited range.
5. Conclusions
In this review we developed a Cav1.4 structural homology model
with the aim to elucidate the structure–(dys)function relationship in
Cav1.x channelopathy mutants in the structural context. We assigned
potential functional ‘hotspots’ for naturally occurring loss- and
gain-of-function mutants. The vast majority of loss-of-function muta-
tions are nested in core channel folding domains whereas all the
gain-of-function mutations sit at the inner mouth of the channel pore
and these gain-of-function mutants interfere with coupling between
the voltage sensor (via the S4–S5 linker) and the channel gate. Cav1.4
mutations with impaired CTM function led previously to the discovery
of a novel inhibitory feedback mechanism in LTCCs that depends on a
gating modiﬁer in the C-terminus. This opened a new ﬁeld of LTCC re-
search that uses this intramolecular modulator as study tool to adjust
intracellular Ca2+ activity. This property might even bear the potential
for a therapeutic application.
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